Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10031827 | 0.92 | PGR (0.47) | PGRARELANECA2HDAC1 | |
| SCHEMBL15745797 | 0.84 | PGR (0.51) | PGRARELANECA2L3MBTL1 | |
| SCHEMBL10483771 | 0.84 | ELANE (0.54) | PGRARELANESRD5A2ALDH1A1 | |
| SCHEMBL11823338 | 0.82 | MAPT (0.50) | PGRARL3MBTL1ALDH1A1LMNA | |
| SCHEMBL759623 | 0.82 | ESR1 (0.52) | ARELANECA2SRD5A2TSHR | |
| SCHEMBL11437940 | 0.82 | PGR (0.42) | PGRARELANECA2HDAC1 | |
| SCHEMBL1665113 | 0.82 | TSHR (0.60) | CA2CES1SRD5A2TP53TSHR | |
| SCHEMBL1665111 | 0.82 | PGR (0.42) | PGRARELANECA2HDAC1 | |
| SCHEMBL1701967 | 0.82 | CA2 (0.57) | CA2HDAC1CES1SRD5A2ALDH1A1 | |
| SCHEMBL24354428 | 0.80 | TPMT (0.52) | PGRARELANECA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7355036-B2 | Two-stage protective groups for the synthesis of biopolymers | FEBIT AG (DE) | 2008-04-08 | — | — | US | disclosed |
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | MR. CHRISTOPHER SEAGON, ESQ. (DE) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197851-A1 | Two-stage protective groups for the synthesis of biopolymers | CTRB2, OGG1, CPB2 | PGR 3917/4885AR 4641/4885ELANE 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.